For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Sexual & Reproductive Health: What the Human Evidence Shows

Content updated · how dates work

Sexual function, reproductive hormones, and obstetric care.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Reproductive health: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for reproductive health: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (6)Approved for the specific uses on its label, which may not be this goal.
BremelanotideRECONNECT (2019) · Human randomized trial
Desire scores improved and distress scores decreased more with treatment. Nausea, flushing, and headache were more frequent.
Limitation: The endpoints were validated symptom scales. These results do not establish treatment for every cause of low desire, male erectile dysfunction, or general sexual performance.
Studied: 1,267 premenopausal women randomized across two studies of hypoactive sexual desire disorder.
FDA-approvedFDA label
DegarelixPRONOUNCE (2021) · Human randomized trial
Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53).
Limitation: Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
Studied: 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900.
FDA-approvedFDA label
HCGHCG and clomiphene in male hypogonadism (2018) · Human randomized comparative trial
Testosterone increased in all three groups, without a significant between-group difference. The combined group had a greater reported improvement in symptom scores.
Limitation: Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims.
Studied: Men with hypogonadism who wished to preserve fertility.
FDA-approvedFDA label
LeuprolideHistorical prostate-cancer comparison (1984) · Human randomized trial
Hormonal suppression and overall response were similar; adverse-effect patterns differed. One-year survival was not significantly different.
Limitation: This is historical evidence against an older comparator, not a ranking of today’s treatment options. Prostate-cancer findings do not establish benefit for every other leuprolide indication.
Studied: 199 patients with previously untreated metastatic prostate cancer.
FDA-approvedFDA label
OxytocinRoute comparison after vaginal birth (2018) · Human randomized trial
The primary bleeding endpoint was not significantly different. Severe postpartum bleeding, a secondary endpoint, occurred in 4.6% versus 8.1%, favoring intravenous administration.
Limitation: Both groups received oxytocin under clinical supervision. This addresses route selection after delivery, not bonding, mood, or unsupervised nasal-spray use.
Studied: 1,075 women randomized; 1,035 included in analyses at an Irish maternity unit.
FDA-approvedFDA label
TriptorelinCombined TEXT / SOFT analysis (2014) · Human randomized combination-treatment trials
Five-year disease-free survival was 91.1% versus 87.3%: hazard ratio 0.72. Overall survival was not significantly different.
Limitation: The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Studied: 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis.
FDA-approvedFDA label
Randomized human trials (1)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
Melanotan IIMelanotan II · organic erectile dysfunction (2000) · Human randomized trial
Erections followed 12 of 19 Melanotan II injections compared with 1 of 21 placebo injections. Severe nausea followed 4 of 19 Melanotan II injections.
Limitation: Very small and short. Side effects were common, and the drug was not approved.
Studied: 10 men with organic erectile dysfunction.
Not approvedTrials only
Small or uncontrolled human studies (3)Human reports without randomization, such as pilots, case series or open-label studies.
GonadorelinMulticenter pulsatile GnRH clinical series (1990) · Human clinical series
Reported ovulation rates were 91% in primary and 96% in secondary amenorrhea. Multiple pregnancies occurred in 12%; intravenous-line complications averaged 7%.
Limitation: These are results from a clinical series, not a randomized estimate of benefit versus another treatment. Specialist monitoring and the precise diagnosis are part of the clinical context.
Studied: 109 women with primary or secondary hypothalamic amenorrhea.
WithdrawnVery limited
Kisspeptin-10LH secretion experiment (2011) · Small human physiology study
LH increased, and infusion changed LH pulse frequency and size. Testosterone also increased in the prolonged-infusion experiment.
Limitation: These are reproductive-hormone endpoints, not pregnancy, live-birth, or sexual-function outcomes. Findings for kisspeptin-10 should not be conflated with trials of kisspeptin-54.
Studied: Healthy men in small bolus and infusion experiments.
Not approvedVery limited
Kisspeptin-54Kisspeptin-54 triggering of egg maturation (2014) · Human dose-ranging study
Egg maturation was observed, and fertilization with embryo transfer occurred in 49 of 53 participants. The study reported 12 clinical pregnancies.
Limitation: This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage.
Studied: 53 women undergoing IVF.
Not approvedVery limited

Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.

Bremelanotide

Bremelanotide is a prescription melanocortin agonist studied for a defined form of low sexual desire associated with distress. It is also known as PT-141.

Prescription medicines

Read the studies →

Degarelix

Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.

Prescription medicines

Read the studies →

Gonadorelin

Gonadorelin is gonadotropin-releasing hormone. A clinical series studied pulsatile administration in women with hypothalamic amenorrhea, a specific reproductive-hormone disorder.

Research topics

Read the studies →

HCG

Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.

Research topics

Read the studies →

Kisspeptin-10

Kisspeptin-10 is a short active kisspeptin sequence studied in reproductive-hormone regulation. Hormonal responses are a starting point for fertility research.

Research topics

Read the studies →

Kisspeptin-54

Kisspeptin-54 is a reproductive-signaling peptide studied as an egg-maturation trigger during IVF. It is a distinct form from the shorter kisspeptin-10 already covered in this directory.

Research topics

Read the studies →

Leuprolide

Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.

Prescription medicines

Read the studies →

Melanotan II

Melanotan II is a synthetic, ring-shaped analog of alpha-MSH that darkens skin by acting on melanocortin receptors throughout the body. About 23 people were given it in small studies from 1996 to 2000; it was never approved, and case reports link it to changing moles, melanoma and other serious harms. It is a different drug from the approved afamelanotide (Scenesse) and bremelanotide (Vyleesi).

Research topics

Read the studies →

Oxytocin

Oxytocin is a peptide hormone used in supervised obstetric care. Its established clinical context should be separated from popular social or wellness claims.

Prescription medicines

Read the studies →

Triptorelin

Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.

Prescription medicines

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →